Big Conversations: In-House Counsel Discuss The Past, Present, and Future of Biosimilars Market Entry in the EU and U.S. (Part 2)

Following on Part 1 of this series, Goodwin and Bristows continue their discussion with senior in-house counsel at the forefront of the biosimilars industry to discuss the pace of biosimilars market entry in the EU and U.S., why it’s been so different in those two markets, and what the future holds. In the second of several segments to be released over the coming weeks, the panel covers topics including the rules for divisionals, considerations for litigating in different venues, whether engaging in the U.S. patent dance is worthwhile, some legislative proposals related to biosimilars in the U.S. and Europe, and regulatory exclusivity periods for biologics.

Moderators: Rob Cerwinski (Partner, Goodwin), Liz Cohen (Partner, Bristows)

Panelists: Rachel Moodie (Vice President of IP Biosimilars, Fresenius), Alastair Sayce (Lead of Biologics IP, Teva), and Neil Trueman (Chief International IP Counsel, Mundipharma)

“The jury [system in the U.S.] fills me with terror on one level, but it depends on what side you’re on and what narrative arguments you’re making.” – Neil Trueman, Chief International IP Counsel, Mundipharma

Download PDF